A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

Age-related Macular Degeneration Clinical Trial

Official title: Pilot Study of L-DOPA Safety and Tolerability in Patients With AMD, and Proof of Concept That L-DOPA Improves Surrogate Biomarkers in Patients With Moderate to Advanced AMD

Status Withdrawn

Clinical Trial Summary

From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years.

L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization.

The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with AMD, and measure the effects on surrogate functional biomarkers of AMD.

Clinical Trial Description

Age-related macular degeneration (AMD) is the most common cause of blindness, in individuals over the age of 50, in the developed world(1,2). AMD becomes more common as people age, and is more common in lightly pigmented individuals(3). AMD appears more common in patients with Parkinson's Disease, than in those without(4). The AREDS nutritional supplements are effective in slowing the progress of intermediate AMD(5). Most AMD is "dry AMD", which progresses relatively slowly and may impair vision, but usually does not lead to legal blindness. There are two forms of AMD, "wet AMD" and geographic atrophy (GA), that can cause more profound vision loss. In aggregate they occur in about 25% patients with AMD(5). Wet AMD is due to new growth of abnormal blood vessels under the retina. The new blood vessels are believed to be due to an excessive release of vascular endothelial growth factor (VEGF) by the retinal pigment epithelium(RPE) cells(6). Wet AMD is now effectively treated with intraocular injections of VEGF inhibitors(2). Geographic Atrophy, the other form of advanced AMD, represents focal death of the RPE cells and overlying neurosensory retina. There is no current treatment for GA. It is suspected that GA is due in part to a localized inflammatory response, damage to RPE cells and loss of RPE cell function(7). It may also be speculated that stimulation of RPE cells to release a potent neurotrophic factor, pigment epithelium derived factor (PEDF) may slow progression of GA.

In 2008, Dr. Brian McKay identified a receptor, G protein coupled receptor #143(GPR143), on the surface of RPE cells and discovered that L-DOPA was the natural ligand or stimulator of GPR143(8). Dr McKay showed that treatment of RPE cells with exogenous L-DOPA resulted in the release of additional PEDF. In subsequent work Dr McKay's group also showed that L-DOPA stimulation of PEDF in RPE cells was also associated with a decrease in VEGF(9). Thus, Dr McKay hypothesized that exogenous L-DOPA may prevent the onset of AMD or progression to wet AMD.

In 2015, Dr McKay and his associates published a paper that showed that patients, who had been treated with L-DOPA, had a delay in the onset of AMD by 8 years, compared to patients who had not been treated with L-DOPA(10). In addition, those who had AMD and went on to develop wet AMD, did so 5 years later than those with no history of L-DOPA treatment(10). L-DOPA is an intermediate in the pigmentation pathway. Dr McKay and his associates suggested that the reason darkly pigmented races do not get AMD nearly as frequently as lighter pigmented races, is that they produce more pigment, and thus more L-DOPA to stimulate GPR143 on RPE cells. According to this hypothesis, the stimulated RPE cells release PEDF and decrease VEGF, which together are responsible for the protective effect.

Since there are no established animal models for AMD, and L-DOPA has a good safety profile in healthy volunteers and patients with Parkinson's disease(11), the Investigators propose a prospective experiment to determine the safety and tolerability of L-DOPA, in a population of patients with AMD. The participants will be made aware of potential side effects of L-DOPA, which are listed in the Informed Consent, during the consent process. Adverse events will be elicited by questioning the participants at each visit. The participants will also be advised to call the site, if they have any medical problem between visits.

The Investigators will also use this safety study to examine whether L-DOPA has a positive effect on surrogate biomarkers of AMD. The surrogate markers to be evaluated are dark adaptation(12,13), best corrected visual acuity (BCVA), low luminance visual acuity(LLVA)(14), and the size and numbers of drusen(15) and reticular pseudodrusen(16). A previous trial, with retinol in 104 patients, significantly improved dark adaptation in 30 days.(17) Therefore, the Investigators expect to see improvement with L-DOPA in a relatively short time. This study will also help the Investigators prepare for a Phase 3 study of L-DOPA in AMD.

Pharmacology of L-DOPA and carbidopa

L-DOPA is formed by 3-hydroxylation of tyrosine by tyrosine-3-monooxygenase (tyrosinase).(18) The primary metabolic pathway of L-DOPA is decarboxylation by amino acid decarboxylase to dopamine, which is responsible for most, but not all, of its pharmacologic effects and toxicity. When carbidopa is administered with L-DOPA, systemic levels of L-DOPA double and central nervous system (CNS) L-DOPA increases from about 1% of the administered dose to about 4%. Levodopa freely passes from the systemic circulation into the retina and brain, but dopamine and carbidopa do not. Adverse events are markedly decreased when carbidopa is administered with L-DOPA, because systemic levels of the toxic metabolite of L-DOPA, dopamine, are markedly reduced. In most patients, 25 mg of carbidopa is sufficient to control side effects of 100 mg of L-DOPA, primarily nausea(18), by 90%. However, some patients require additional supplemental carbidopa. Carbidopa has very limited side effects when given alone(18). Therefore, the Investigators plan to use 35 mg of carbidopa with each 100 mg of levodopa, in order to control adverse events in almost all participants.

L-DOPA is the natural ligand for GPR143 in the RPE cells(8). The Investigators' intent is to increase the L-DOPA available to RPE surface receptors (GPR 143) while minimizing peripheral toxicity. This concept is unique, because all other uses of L-DOPA rely on CNS conversion of L-DOPA to dopamine, in order to produce the desired effect(19).

Treatments:

1. Carbidopa-levodopa 35-100 mg dosed hs for 45 days, followed by carbidopa-levodopa 35-100 mg dosed in the morning, with supper and hs for 45 days. The second dosing period is the equivalent of a moderate dose of carbidopa-levodopa in patients with Parkinson's disease (maximum daily dose 200-800 mg).

2. Placebo dosed hs for 45 days, followed by placebo dosed in the morning, with supper and hs for 45 days.

Placebo and active medication will be dosed as capsules, identical in appearance.

Number of participants: Not yet recruiting, stratified by non-study eye being normal, dry AMD or wet AMD and randomized using a table of random numbers. Estimated screen failure rate is 50%. The sample size is based on a successful study treating patients with impaired dark adaptation with retinol, which showed significant improvement in 30 days with 52 patients per study arm.

Duration: 87-114 days (80-100 days of treatment). Visits 1 (screening) and 2(randomization) can be scheduled within 1 week. The first visit after Randomization, Visit 3, will occur 40-50 days after Visit 2. Visit 4 (end of study) will occur 40-50 days after Visit 3. This schedule allows a 10 day window for study visits, for logistic reasons and patient convenience.

Overall trial duration for enrollment and treatment, screening 5 patients per week, will be approximately 10 months.

Primary Endpoint: A statistically significant improvement by carbidopa-levodopa treatment in any of: dark adaptation; BCVA; LLVA; drusen or reticular pseudodrusen measured by spectral domain(SD) optical coherence tomography(OCT)

Measurements:

1. Demographics at Visit 1;

2. Medical History and Physical Examination at Visit 1;

3. Electrocardiogram(ECG), complete blood count(CBC), Chem 20 and HbA1C at Visit 1;

4. Vital signs at Visits 1,3,4,5 and 6;

5. Non-directed assessment of adverse events at Visits 1,2, 3 and 4;

6. Ophthalmic history and comprehensive eye examination, including dark adaptation and SD OCT at Visit 2 (Baseline);

7. Low luminance questionnaire at visits 2, 3 and 4;

8. Pill count at Visits 3 and 4;

9. Re-measurement of dark adaptation, visual acuity under normal and low light conditions and SD OCT at Visits 3 and 4 (End of Study);

Statistics: Analysis of Variance with Independent Variables:

1. Active Drug vs Placebo;

2. Logarithm of daily dose of active drug;

3. Duration of treatment (measurements at Visits 3, 4, 5 and 6. ;

Related Conditions & MeSH terms

• Age-related Macular Degeneration
• Macular Degeneration

• NCT number: NCT02873351
• Study type: Interventional
• Source: Snyder, Robert W., M.D., Ph.D., P.C.
• Status: Withdrawn
• Phase: Phase 2
• Start date: September 2019
• Completion date: December 2020